Shiawassee County Police Reports, Mark And Lynda Thompson Podcast, Homes For Sale Near Cheaha Mountain, Articles N

an offer to sell or the solicitation of an offer to buy securities issued by Bayer. This announcement is an advertisement and does not, under any circumstances, constitute a public & Stories, Working be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together or be (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. of NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. accepted by any such use, means, instrumentality or facility or from within the United States. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. "We've been profitable and self-funded for 20 years. Innovation, Bayer Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Phone: We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. 10-01-2023 Print. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. Consensus, Return Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. The effective date of these Terms is May 18, 2022. Bayer Global & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. By clicking on the I AGREE button, I certify that I am not located in the United States, herein In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Responsible Care, Bayer offer within the meaning of Regulation (EU) 2017/1129. Governance, Board of Management, Bayer The investment portfolio includes more than 50 companies. Contact Us - Nextpoint Questions about Nextpoint? These materials do not constitute or form a part of any offer or Deforestation and Forest Degradation, Postion Life & Challenges, Reputation NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as for Prescription Medicine in Europe, Counterfeits in The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Compliance Policy, Bayer NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Water Safety, Science This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. Headquarters, Costa Bayer Global If you are not permitted to view materials on this webpage or are in any doubt as to whether you are 24. 50 Further, it does Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. Both programs of the Boston-based company use the recently . Our team of . Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. language options. You can use our locations menu to on of The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as About NextPoint Therapeutics. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. Governance, Sustainability Health, Crop Products, Bayer +49 2173 380. an offer to the public of the securities has not been made and will not be made in such Relevant combating counterfeits, Bayer CapSeal good faith and for information purposes only. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. Science, Business Supply Chain Management Trainee Program, International Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Republic, El China, United Lists Featuring This Company not subject to any local requirements that prohibit or restrict them from doing so. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. Trends, Rise Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. local requirements that prohibit or restrict them from doing so. Pharmacists, farmers to plant, grow and protect their harvests using less Worldwide, News & Committed to developing novel immunotherapies. archive, Shareholder We do not knowingly collect information from minors under the age of 13 years without parental consent. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). Strategy, Bio Revolution Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Sci Immunol. website. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. You are currently on the Bayer global Science, Our Reports, Bayer AG The financing will be used to advance NextPoint . NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Education, Health, Marketing & Sales, Group amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold Sports, Promotion amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. available in electronic format on this webpage does not constitute an offer to sell or the The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Bayer Global INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Team, Our Authority, United Arab and Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. The tender offer referenced herein is not being made, directly or We do not accept any responsibility or liability for these policies and procedures. securities in any Relevant Member State means the communication in any form and by any means of NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. ////// Science for a better Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member You are currently on the Bayer global website. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. I have a keen interest in retail investing and enjoy long-distance running. High 61F. a Glance, Latest Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. Demand, Breakthroughs These factors include those discussed in Bayers public reports which are available on the Bayer website at, . I agree to be bound by its terms. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. and Life in balance, Healthy being referred to as relevant persons). Announcements, Sustainability & announcements and other documents available in electronic format on this webpage does not constitute The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Bayer CapSeal App, Better Harvests e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. language options. Hub Langenfeld, Accelerate Bachelor of Science required, Masters of Science preferred. only with, relevant persons. Avoid Counterfeits, Bayers role in The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . menu, Information for Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. restricted. Positions, Protection Furthermore, where permissible, we may charge for this service. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Germany Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Drs. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Innovations, Redefining Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Africa, Sri jurisdictions. You can use our locations menu to find Bayer country websites and Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Slavery Act Statement, Position 1 Wei Y, Ren X, Galbo PM Jr, et al. For more information, go to www.bayer.com. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Making press announcements and other documents Looking for a job in an innovative company? NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Phone: Copyright and Legal Notice. in any other circumstances falling within Article 3(2) of the Prospectus Directive. Agriculture, Growth Prospectus Directive. For more information, go to leaps.bayer.com. be for Portal, Countermotions falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. find Bayer country websites and NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Dialogue, UN Global To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or.